Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
Conclusions Weight loss at presentation had a detrimental impact on PFS and OS in EGFR-TKI sensitive mutant advanced NSCLC patients treated with first-line EGFR-TKI. It should be considered as an important factor in the treatment decision or designing of EGFR-TKI clinical trials.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Liping Lin, Juanjuan Zhao, Jiazhu Hu, Fuxi Huang, Jianjun Han, Yan He, Xiaolong Cao Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva | Weight Loss